

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AIM Vaccine Co., Ltd.
艾美疫苗股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 06660)

VOLUNTARY ANNOUNCEMENT
SECOND GENERATION OF HIGHLY-EFFECTIVE
ABSORBED TETANUS VACCINE OBTAINED
THE CLINICAL TRIAL APPROVAL

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

The clinical trial approval for the Group’s second generation of highly-effective absorbed tetanus vaccine has been recently obtained from the National Medical Products Administration, which marks a new progress of the research and development of the vaccine.

Tetanus is an extremely serious and potentially fatal disease, and tetanus vaccination is currently the most cost-effective and effective measure to prevent it. In addition, the Group is actively promoting the research and development of diphtheria, tetanus and acellular pertussis – HIB combined vaccine (the “**Tetravaccine**”), pentavalent vaccine and other multidisease vaccine. Among them, the Tetravaccine is used to prevent invasive infections caused by pertussis, diphtheria, tetanus and Haemophilus Influenzae type b, and has the advantages of reducing the number of vaccinations for infants and young children, and enhancing the vaccination compliance of parents, infants and young children. The development of multidisease vaccine has become a trend in the industry. According to the data of China Insights Industry Consultancy Limited, an industry consultant, the Chinese market size of the multidisease vaccine is expected to reach RMB10 billion in 2030.

The research and development of the vaccine is in line with the Group's strategic layout in product research and development and is an important step to realize the Group's research and development of multidisease and multivalent products, which will further improve the Group's product pipelines, help the Group enrich its product line and consolidate its industry position, and achieve sustainable and rapid growth in the Group's performance.

By order of the Board
AIM Vaccine Co., Ltd.
Mr. Yan ZHOU

*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, December 19, 2024

As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Wen GUAN, Mr. Shaojun JIA and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Hui OUYANG, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.